Suven Life Sciences secures two patents

These patents are valid until 2029 and 2030 respectively

Suven Life Sciences has been granted a patent each by Eurasia and Israel for a drug used in the treatment of neuro-degenerative diseases.

The company has been granted one product patent from Eurasia and one product patent from Israel corresponding to the New Chemical Entities (NCEs) for the for the treatment of disorders associated with neuro-degenerative diseases," the company said in a BSE filing.

These patents are valid until 2029 and 2030 respectively.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for major depressive disorder (MDD) with high unmet medical need with huge market potential globally," said Mr Venkat Jasti, CEO, Suven Life Sciences, in a statement.